A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi- Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability Patients With Mild to Moderate Onychomycosis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 May 2017
At a glance
- Drugs NP 213 (Primary)
- Indications Onychomycosis
- Focus Therapeutic Use
- Sponsors Taro Pharmaceuticals USA
- 16 Mar 2017 Planned End Date changed from 1 Jun 2017 to 30 Jun 2018.
- 16 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 8 May 2018.
- 16 Mar 2017 Status changed from recruiting to active, no longer recruiting.